C4 Therapeutics: Pay

C4 Therapeutics paid its 3 named executives $6.1M in total in FY2025 (Dec). CEO Andrew J. Hirsch was paid $2.9M of that.

Pay$100 in the stock at the end of FY21 → $6
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Andrew J. HirschPresident & Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Leonard Reyno, M.D.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Kendra R. AdamsChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 13 peers with pay on file was $4.2M. The CEO of C4 Therapeutics was paid $2.9M, 30% below the median.

  1. 1Kymera Therapeutics
  2. 2Arvinas
  3. 3Nurix Therapeutics
  4. 4Oric Pharmaceuticals
  5. 5Cullinan Therapeutics
  6. 6Relay Therapeutics
  7. 7Lyell Immunopharma
  8. 8Fulcrum Therapeutics
  9. 9Nkarta
  10. 10C4 Therapeutics
  11. 11Tango Therapeutics
  12. 12Editas Medicine
  13. 13Black Diamond Therapeutics
  14. 14Adicet Bio
  15. 15Foghorn TherapeuticsNot disclosed
  16. 16IGM Biosciences, Inc.Not disclosed
  17. 17Monte Rosa TherapeuticsNot disclosed
  18. 18Poseida Therapeutics, Inc.Not disclosed
  19. 19Prelude Therapeutics IncorporatedNot disclosed
  20. 20Sutro BiopharmaNot disclosed
  21. 21iTeos Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.